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Background: Patients in advanced stages of chronic kidney disease (CKD), especially patients 
treated with dialysis, have reduced physical capacity. The main objective of this project was 
to study and compare the degree of physical activity (PA) in patients in haemodialysis (HD) 
and peritoneal dialysis (PD) in Nordland, Troms and Finnmark. To our knowledge this is the 
first study to include accelerometer recordings of patients in both HD and PD.  
Methods: An observational study was conducted during 15. November to 15. December 
2018. Patients were recruited in hospitals and dialysis satellites by mainly nephrologist and 
dialysis nurses. Each patient participated voluntarily and signed a written consent. The study 
consisted of a self-administered questionnaire about PA and health-related quality of life, 
and accelerometer recordings for seven days for objective measurements of PA.  
Results: Thirty patients out of 181 on chronic dialysis participated in the study, whereas 22 
in HD and 8 in PD. Twenty-eight percent of all invited patients consented and were included 
in the study. Median wear time for ActiGraph accelerometer was significantly higher (P < 
0,05) in the HD group with 9194,5 (8501-9733) minutes compared to PD 7509 (6400-9134) 
minutes. Seven out of 22 HD patients (31,8%) and five out of eight PD patients (62,5%) 
reached the recommended weekly goal of ≥ 150 minutes moderate-to-vigorous physical 
activity (MVPA). Only one patient had an active lifestyle in terms of average steps daily (≥ 
7500), three patients classified to somewhat active (5000-7499 steps/day), whereas 26 were 
categorised as sedentary. Haemoglobin was significantly associated with daily MVPA at or 
above vs. below median (OR 0,39 (95% CI 0,15-0,99) per 1 g/dL increase; P = 0,047). Most 
patients reported that they had never been informed by their nephrologist about the 
potential benefit of being physically active, but a desire to be more active was commonly 
found. 
Conclusion: Results from this study indicate that dialysis patients have a low level of PA 
based on average daily MVPA and step count, compared to healthy people. We found no 
significant differences between patients on the two different dialysis modalities. A high 
haemoglobin level was associated with less daily MVPA. There seems to be a potential for 
increased level of PA in dialysis patients, and efforts should be made by health care 
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Patients in advanced stages of chronic kidney disease (CKD), especially patients treated with 
dialysis, have reduced physical capacity. The causes are complex. A high share of patients in 
chronic dialysis have comprehensive comorbidity, often cardiovascular disease, diabetes 
mellitus and frequent infections (1). Many patients on dialysis are prescribed and use 
numerous drugs, making them susceptible for side effects that may impair quality of life. 
CKD includes retention of uraemic toxins that affect other organs (cardiovascular system, 
bone marrow, endocrine organs, cognitive functions) and the disease is also associated with 
subjective symptoms such as nausea, impaired quality of sleep, depression and reduced 
general well-being (2, 3). Finally, dialysis treatment itself is associated with several adverse 
effects and a high risk of complications. Moreover, the treatment is time consuming and 
exhausting for patients over time. Patients undergoing treatment with dialysis have reduced 
exercise tolerance compared with age-matched sedentary controls (4). There are also 
indications that patients undergoing dialysis have difficulties being physically active, and 
therefore may often have a sedentary lifestyle. The reasons behind the low amount of 
physical activity (PA) is not fully known, but the above-mentioned factors may contribute to 
a low activity lifestyle.  
1.1 Definition of chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) 
According to the Kidney Disease: Improving Global Outcomes (KDIGO, 2012) CKD is defined 
as abnormalities of kidney structure or function, present for >3 months, with implications for 
health (5). The period of three months is set to distinguish between acute kidney diseases 
and CKD. CKD is diagnosed if one or more of the following criteria are present >3 months; 
markers of kidney damage and/or decreased glomerular filtration rate (GFR). Albuminuria is 
often used as marker of kidney damage, being an indicator of increased glomerular 
permeability and/or dysfunction of proximal tubular reabsorption. KDGIO guidelines 
recommend CKD classified into stages based on measurements of GFR and albuminuria (5). 





>90 ml/min/1.73 m2) to G5 (GFR <15 ml/min/1.73 m2, or kidney failure)(5). End-stage renal 
disease (ESRD) is generally acknowledged as kidney failure treated with renal replacement 
therapy (RRT) (1).  
1.2 Treatment of ESRD 
ESRD is generally treated with dialysis or renal transplantation, both included in the term 
RRT (6). Kidney transplantation has been shown to be the most desired and cost-effective 
treatment for suitable patients with ESRD (7). Dialysis is divided in peritoneal dialysis (PD) 
and haemodialysis (HD). 
1.2.1 Peritoneal dialysis (PD) 
The principles of PD are based on the use of the peritoneal membrane as the dialyzing 
surface. Waste and excess fluids are removed from the vascular system, through the 
peritoneal capillary blood, into the dialysis solution instilled in the peritoneal cavity through 
a catheter(8). The dialysis solution contains an osmotic agent, usually glucose, creating the 
osmotic gradient that moves fluid from the capillaries to the peritoneal cavity, while solute 
removal is the result of diffusion and convective transport over the membrane (6). Most PD 
patients use one form of continuous dialysis, implying that the dialysis solution is always 
present in the peritoneal cavity except during the out- and in-flow of the fluid. In continuous 
ambulatory PD (CAPD) the solution is exchanged 4-5 times a day, usually by the patient, 
whereas a machine takes care of fluid exchanges in automatic PD (APD), mainly during the 
night. Thus, PD is the most common modality of home dialysis. Most patients carry out the 
treatment themselves, whereas other patients need additional help from homecare 
personnel (assisted PD).  Treatment with PD allows patients to participate in normal daily 
activities between the exchanges of the peritoneal fluid. 
1.2.2 Haemodialysis (HD) 
Haemodialysis is an extracorporeal treatment based on a dialyzer with a semipermeable 
membrane. HD requires a vascular access, either an arteriovenous (AV-)fistula or a central 
venous catheter (CVC), to allow blood to be transported from the patient through the 





principle of HD involves diffusion and convection of solutes across the dialyser membrane. 
Diffusion refers to the movement of solutes from higher concentrations in the blood to the 
lower concentrations in the dialysate fluid, whereas convection is the mass transport of fluid 
and solutes driven by a higher hydrostatic pressure in the blood compartment, generated by 
the blood pump of the dialysis machine (8). The treatment usually takes place 2-5 times per 
week at a hospital centre or in a dialysis satellite unit  in sessions of 3-5 hours (9). HD 
requires patients to travel to treatment and use a considerable amount of time during each 
session, which is demanding for the patient. However, home HD treatment is also available 
for adherent and motivated patients. 
1.2.3 Kidney transplantation  
Kidney transplantation is associated with better observed mortality and morbidity rates, 
quality of life and participation in activities than dialysis (7, 9, 10) and therefore is the 
preferred RRT in patients with ESRD.  Due to the high prevalence of comorbidity in ESRD, as 
well as to the need for life-long therapy with immunosuppressive drugs, all patients 
considered for kidney transplantation must go through a thorough evaluation to rule out 
malignant diseases, chronic infections and extensive cardiovascular disease that must be 
treated before transplantation, or that may rule out transplantation as a treatment of 
choice. Also, non-adherent patients are not eligible for transplantation. We should aim for 
early referral of patients who need kidney transplantation, and who do not have known 
contraindications, to an evaluation program to assess if they are suitable for the treatment. 
In kidney transplantation, the source of the graft may be either a living donor, which is 
preferred due to an even better prognosis, or a deceased donor (11). In Norway the waiting 
list for organs is relatively short, indicating that most patient eligible for transplantation 
eventually are transplanted within 1-2 years (12). Thus, in Norway patients on long term 
dialysis in general are older and have more comorbidity than patients on the waiting list for 
transplantation. 
1.3 Physical activity and kidney disease 
The positive effects of PA in the general population is well documented. The World Health 





the risk of coronary heart disease and stroke, diabetes, hypertension, colon cancer, breast 
cancer and depression in the general population (13). Studies have also shown that PA is 
positively correlated with psychological wellbeing, weight control, building and maintenance 
of healthy bones, muscles and joints (14). Regardless of the positive effects of PA, some data 
show that 31-32% of the world’s adult population do not meet the minimum 
recommendations for PA (15, 16). Current recommendations suggest moderate PA for 150 
minutes a week or 75 minutes’ vigorous PA during a week in bouts of minimum 10 minutes, 
or an equivalent of moderate-to-vigorous intensity activity. For example, 30 minutes of 
moderate-to-vigorous physical activity (MVPA) 5 times a week is sufficient for people 
between 18-64 years old (13). This also applies to people over 65 years old. 
1.3.1 Existing knowledge and knowledge gaps regarding physical activity in ESRD.  
Even if some observational studies have shown that the level of PA among patients on 
dialysis is low, results from observational studies (17-19) and small intervention studies have 
demonstrated that increased physical exercise in this patient group is associated with better 
outcome(20, 21), in terms of proxy measures as arterial stiffness and health-related quality 
of life (HRQOL). One systematic review has shown that aerobic exercise made an 
improvement in physical fitness, muscular strength and quality of life in ESRD patients (21). 
In 2017 a retrospective cohort study concluded that high levels of PA was associated with 
favourable results in HRQoL scale scores, including frailty, disability and exhaustion (18). 
Therefore, some do think that patients on dialysis should be recommended the same 
amount of PA as people > 65 years (22). 
To counsel the patients and to implement targeted intervention more knowledge about the 
type and quantity of PA applied by patients in this group is necessary. Most of the published 
observational studies on quantification of PA have used questionnaires. Today we know only 
of two small studies in which activity monitors were used to assess the type and amount of 
PA in patients in HD treatment (23, 24). We do not know of equivalent studies on patients in 
PD treatment, and therefore we do not have data that compare the two groups of patients. 
As far as we know, no activity measurements within patients in ESRD in HD or PD treatment 





1.3.2 Methods to assess physical activity 
1.3.2.1 Questionnaires 
The use of questionnaires in studies regarding PA and health-related quality of life are 
broad. Many earlier studies have used standardised questionnaires due to their easy-to-use 
properties, economically favourable and acceptably validated qualities. Scoring manuals 
allow the results to be compared to other studies. Well renowned questionnaires do have 
weaknesses because information is self-reported from the patients, and therefore allow 
subjective interpretations of questions, communication barriers, and 
overestimating/underestimating to happen. Overestimating PA, especially in moderate 
intensity, are shown in different countries (24). There are also studies that show a weak 
relationship between self-reported PA in questionnaires and objectively measured PA with 
heart rate monitor and movement sensor (24). Therefore, self-reported data should be 
interpreted with caution.  
1.3.2.2 IPAQ 
IPAQ is a questionnaire designed to classify individuals in activity categories related to 
current recommendations for PA (16). The questionnaire is validated in 12 countries, mainly 
in populations between 18-65 years old in diverse settings, with acceptable measurement 
properties (25). The short form consists of seven questions about PA during the last seven 
days, with questions about amount of activity and intensity, walking and time spent sitting. 
IPAQ short form has been tested and used in many international studies (26). The IPAQ short 
form has previously been used to assess PA in patients with CKD not requiring dialysis and in 
patients with CKD undergoing haemodialysis (27, 28). 
1.3.2.3 KDQOL-SF 1.3 
KDQOL-SF is a self-reporting instrument to assess particular concerns of people with kidney 
disease and dialysis (23). The Norwegian translated questionnaire has thirty-three questions 
related to the kidney disease, including symptoms, effect of kidney disease on daily life, 
burden of kidney disease, work status, cognitive function, sexual function, sleep, social 





KDQOL-SF have been used in international studies of HRQOL in ESRD patients (30), and the 
reliability of the Danish version has been tested in Denmark with the same internal 
consistency as the original U.S English version (31).  
1.3.3 Accelerometers 
Accelerometers are useful in collecting body movement objectively and may so contribute 
with information about total amount, intensity, duration and frequency of PA (32). Thus, the 
use of accelerometers has lately become more regular in epidemiologic and clinical studies. 
Accelerometers are motion sensors that measure movement accelerations in one or more 
directions to calculate movement in the subject wearing them. Today, we often use 
electronic uniaxial (usually vertical plane) and triaxial accelerometers (anteroposterior, 
mediolateral and vertical directions). The electronic motion sensors consist of piezo-resistive 
or piezo-electric sensors. Piezo-resistive accelerometers require an external power source 
due to registration of accelerations by change in resistance of silicon resistors, which is then 
transformed to a voltage proportional to the amplitude and frequency of the acceleration. 
This will also allow them to respond to constant acceleration such as gravity (33). Piezo-
electric accelerometer will not respond to constant gravity as they generate an electric 
charge in response to a mechanical force. However, they will not be dependent on an 
external power supply to operate (33). Some accelerometers have additional features such 
as the ability to measure heart rate, lighting, body temperature etc.  
2 Beneficial value of the study 
It is presumed that the level of PA of patients in dialysis is significantly lower than 
recommended. Some studies have shown favourable effects of a higher PA level in this 
group of patients. However, we know little about the actual activity level of dialysis patients 
in general, and in Northern Norway in particular, which we want to assess in this study. We 
believe this is essential and basic knowledge to better implement targeted and effective 
measures to increase the amount PA and therefore increase quality of life while reducing 






3 Hypotheses and aims of the study 
3.1 Hypotheses 
Our hypothesis is that the general level of activity in dialysis patients, assessed using an 
accelerometer, is low; lower than the general population within the same age group. We 
also hypothesise that patients in PD have a higher level of activity compared to patients in 
HD. Finally, we believe that the degree of comorbidity has a negative influence on the 
amount of PA exercised in this group of patients.  
3.2 Aims of the study 
In the present project, we aimed to: 
- examine if registration with the accelerometer is a suitable method for studying PA in 
dialysis patients. 
- study the degree of PA of patients in HD and PD in Nordland, Troms and Finnmark. 
- To map out biological factors that are associated with the amount of PA in dialysis 
patients. 
- To study potential factors that limit the amount of PA carried out by patients in HD 
and PD. 
4 Material and methods 
4.1 Ethics 
This is an observational study where PA was measured through an unharmful and painless 
method. Participation in the study was based on written informed consent from all patients 
included. The Data Protector Officer of involved institutions have approved the protocol. 
The Regional Committee for Medical and Health Research Ethics has evaluated the protocol 
and concluded that the Health Research Act does not apply due to the scope and design of 





4.2 Study population 
The study is an observational pilot study aimed to measure PA objectively, and to collect 
information about the quality of life in prevalent dialysis patients treated with either HD or 
PD in Northern Norway. Northern Norway consists of three counties (Finnmark, Troms and 
Nordland), cover an area of 112 973 square kilometres and have 486 001 inhabitants 
(01.01.2018) (34). There are four hospital trusts (Finnmarkssykehuset, Universitetssykehuset 
Nord-Norge (UNN), Nordlandssykehuset, Helgelandssykehuset) in Helse Nord’s regional 
health authority. The two main hospital dialysis centres are in Bodø and Tromsø, for HD and 
PD. These centres initiate HD-treatment and PD-treatment in Northern Norway. Specialists 
in nephrology are also located in Sandnessjøen (Helgelandssykehuset), Kirkenes 
(Finnmarkssykehuset) and Harstad (UNN). Furthermore 15 dialysis satellite units, situated in 
local hospitals as well as in primary care centres, contribute with HD (35).  
Patients in HD treatment were invited to participate when they arrived at their treatment 
centre, either by a project partner or collaborating doctor or nurse. Patients established in 
PD were invited to participate during a regular visit to the hospital, or per letter or telephone 
by a project collaborator/partner. All eligible participants interested in the project received 
written information. Project partners made sure the written information was understood, 
and we obtained a written consent from all included patients. Participants gave their 
consent to the collection of data mentioned below, and to project partners to access their 
patient records to collect relevant background information, and to the collection of follow-
up data in a potential follow-up-project relevant for this study.  
4.2.1 Inclusion and exclusion criteria 
All patients >18 years old, able to give their written consent and who had been on treatment 
with HD or PD > 3months and received follow-up by a nephrologist in Nordland, Troms or 
Finnmark were eligible for the study. 
Exclusion criteria were; 





- Admittance to hospital during the last 4 weeks due to acute illness (patients may be 
included in the study 4 weeks after discharge from the hospital) 
- Patients considered by a nephrologist as not suitable due to a high load of physical 
and/or mental comorbidity 
- Patients unable to walk 
4.3 Health-related quality of life and physical activity questionnaires  
Immediately after the receipt of their written consent, each patient was given a self-
administered questionnaire. The questionnaire was composed with the use of questions 
from the following validated questionnaires; KDQOL-SFTM 1.3 (Norwegian short form) (29) 
and IPAQ (Norwegian short form) (16).  
Data from KDQOL SF-questions were scored from 0-100, where a higher score reflects a 
better quality of life, in following domains; physical functioning, role limitations due to 
physical health problems, role limitations due to emotional health problems, emotional well-
being and energy/fatigue.  
Data from IPAQ questions were summarized to quantify self-reported PA into three levels; 
High (equivalent to ≥ 1-hour moderate/vigorous activity daily), moderate (equivalent to half 
an hour of ≥ moderate/vigorous intensity PA on most days) and low (not meeting any of the 
criteria of moderate or high levels of PA). In addition, we composed questions to study what 
the patient acknowledges as barriers towards participating in more PA. These questions 
were scored in four categories (“no barrier”, “low barrier”, “moderate barrier”, “high 
barrier”) to give an indication of the challenges our patients must face. The questionnaire 
used in the study is included in the appendix (Appendix 1). 
4.4 Objective assessment of physical activity 
Objective measurements of PA were collected with ActiGraph GT3X accelerometer, which is 
among the best validated devices (32, 36) and has recently been used in The Tromsø Study 
2015-2016. The ActiGraph GT3X is a piezo-electric device that is small (4.6 x 3.3 x 1.5 cm), 





the study, the subjects placed the ActiGraph on their right hip with 100Hz sampling rate for 
8 days with a recording time of 7 full calendar days.  
We used the ActiLife v6.13.3 software to extract data from ActiGraph monitors. Data were 
extracted into 10 seconds EPOCH. EPOCH are essentially raw data that have been filtered 
and summed up into chunks of data. The raw data can then be viewed in time-defined 
chunks of 10, 15, 30 or 60 seconds, and so on. Dividing raw data into EPOCH data is 
necessary to use algorithms to produce outputs. Wear-time validation was performed using 
the Choi 2011 algorithm; 1) zero-count threshold during a non-wear time interval, 2) 90-min 
time window for consecutive zero/nonzero counts, and 3) allowance of 2-min interval of 
nonzero counts with the up/downstream 30-min consecutive zero counts window for 
detection of artifactual movements (37). Sedentary bouts were defined from a minimum 
length of 10 minutes, with minimum count value 0 and maximum count value 99 in the 
ActiGraph. Average time per sedentary bouts during a period is given in minutes. Freedson 
Adult VM3 algorithm uses all three of ActiGraph’s axes to calculate motion and was used to 
calculate minutes of light activity (< 2690 counts per minute), moderate to vigorous activity 
(MVPA ≥ 2691 counts per minute). Light activity and MVPA are also measured in percent of 
total time. ActiGraph measured the daily number of steps, and we classified subjects into 
three categories based on average daily step count: sedentary (< 5000 steps/day), somewhat 
active (5000-7499 steps/day), or active (≥ 7500 steps/day) (38).  
4.5 Data collection 
We collected the following data from patient records: 
- Demographical data (age, gender, marital status) 
- Type and duration of RRT 
- Travel distance and time spent for travelling to dialysis centre/nephrologist 
- Comorbidity (Carlson’s comorbidity index) 
- Current drug use  
- Smoking (never smoked, previous smoker, current smoker; pack years) 





- Laboratory test (blood samples measured in timeframe +/- 4 weeks from inclusion):  
Haemoglobin, leucocyte count, albumin, ionised calcium, phosphate, parathyroid 
hormone, bicarbonate, creatinine, carbamide, HbA1c, cholesterol. For patients on 
HD, we used predialytic values. 
4.6 Statistical Analysis 
Statistical analyses were performed using SPSS version 25 for Windows. Frequencies and 
percentages were calculated using descriptive statistics. Data are given in median 
(interquartile range). To show comparison between groups, the nonparametric independent 
samples test Mann-Whitney U test was used. Chi-Square test was used for between-group 
comparisons of dichotomous variables, and these are expressed in percentages. Univariate 
correlation was performed for the variables; age, body mass index (BMI), diabetes, number 
of drugs, haemoglobin, albumin and creatinine, and r values are listed with Spearman 
correlation coefficient. Logistic regression analysis was used to check for predictors for 
higher activity. The following predictors were included in models: age, BMI, diabetes, 
number of drugs, haemoglobin, albumin and creatinine. The level of significance was set at P 
< 0,05. 
4.6.1 Power calculation 
We recognise this pilot project as a descriptive survey of PA of dialysis patients in Northern 
Norway Regional Health Authority. PA measurement has never previously been 
accomplished using this method in a comparable cohort. Therefore, precise power 
calculations cannot be done. Study of factors associated with the amount of activity are 
secondary objectives. At the time of inclusion, the total number of patients in HD 







5.1 Study population 
The selection of participating patients is shown in Figure 1. Of 42 patients on PD and 139 HD 
patients, 74 were not invited to participate in the study, for various logistic reasons, or 
because they fulfilled one or more of the exclusion criteria. A total of 37 patients consented 
to participate in the study, but seven were excluded due to dialysis vintage < 3 months (n=1), 
acute illness (n=3) or withdrawal of consent to participation (n=3), resulting in a total of 30 
patients in the study. Twenty-eight percent of all asked patients participated in the study 
and were analysed. 
 
The characteristics of the HD patients and PD patients in the study are shown in Table 1. 
Median age, gender distribution, marital status, percentage of transplantation candidates, 
number of medications, comorbidities, BMI and laboratory data were all similar between the 
HD-patients and PD-patients. The distance to dialysis centre in kilometres was significantly 
higher in the PD-patients group (P < 0,05). 





Table 1: Characteristics of haemodialysis (HD) patients and peritoneal dialysis (PD) patients. 
Characteristics HD patients (n=22) PD patients (n=8) P 
Age (years) 69 (55,5-78,5) 64 (61,3-76) 0,945 
Male (%) 15 (68,2%) 5 (62,5%) 0,77 
Marital status 
    Single 
    Widowed or divorced 










Duration of treatment (months) 1 25 (13-43,5)1 16,5 (6,3-27,8) 0,168 
Transplantation candidate – yes (%) 13 (59,1%) 6 (75%) 0,424 
Number of drugs 12,5 (10-17,3) 13 (11,5-15) 0,621 
Distance to dialysis centre (km) 9 16 (6-65) 7 255 (75,9-362,5) 2 0,01 
Comorbidities  
    Diabetes - yes (%) 
    Heart attack - yes (%)1 
    Congestive heart failure - yes (%) 
    COPD - yes (%)1 



















BMI (kg/m2) 25,9 (23,1-30,4) 29,2 (25-30,1) 0,534 
Laboratory 
    Haemoglobin (g/dL)1 
    Leucocytes (x 10^9/mL)1 
    Albumin (g/L)1 
    Ionized Calcium (mmol/L)2 
    Phosphate (mmol/L)2 
    PTH (pmol/L) 2 
    Creatinine (µmol/L) 1 
    Carbamide (mmol/L) 1 
    HbA1c (mmol/mol) 5 










37,0 (29,3-59,3) 2 






1,7 (1,35-2,15) 2 
28,1 (14,9-71,8) 2 
651 (440-712) 1 
20,1 (18,5-22) 1 













    
Data are shown in median (interquartile range) and number (percent). Numbers in xx indicates missing cases. 
5.2 Physical activity 
5.2.1 Self-reported recordings 
Table 2 shows the results for self-reported PA and HRQOL for both patient groups. There 
were no significant differences between the groups in self-reported PA or SF-questionnaire 
domains. For role limitations due to physical health, between-group difference reached 
borderline significance (p=0,053) No patients performed vigorous training during the last 







Table 2: Self-reported physical activity (PA) of HD patients and PD patients. 
Physical activity HD patients (n=22) PD patients (n= 8) P 





Days during last week with vigorous activity? 
- None 
- 1 or more days 
- Missing 
Days during the last week with moderate activity? 
- None 
- 2 days 
- 4 days 
- 5 days 
- Missing 
Days during the last week with 10 minutes walking? 
- None 
- 1 day 
- 2 days 
- 3 days 
- 4 days 
- 5 days 


































































Time spent sedentary during a normal day? 
- No of patients responding in minutes    
       - How many minutes? 

















KDQOL-SFTM 1.3 domains (0-100)    
   Physical functioning 50 (42,5-67,5) 17 65 (22,5-92,5) 6 0,516 
   Physical role functioning 0 (0-12,5) 17 75 (0-100) 7 0,053 
   Emotional wellbeing 80 (73-84) 16 86 (58-97) 6 0,590 
   Emotional role functioning 41,7 (16,7-66,7) 16 66,7 (0-66,7) 7 0,734 
   Energy/fatigue 37,5 (30-50) 16 47,5 (11,2-70) 6 0,590 
Data are shown in median (interquartile range) and number (percent). Numbers in xx indicates valid cases.  
5.2.2 Accelerometer recordings 
All participants wore their accelerometer during the study. Range for wear time: 5h 9min to 
7 days). Median wear time for ActiGraph accelerometer was significantly higher (P < 0,05) in 
the HD group compared to PD (Table 3). In total, participants contributed with ActiGraph 
recordings spread out over a total of 206 days, 137 in the HD group and 39 in the PD group, 
with a total wear time of 176 full days. There were no further significant differences in the 
ActiGraph measurements between the HD and the PD patients. Total MVPA time and MVPA 
as percent of wear time were not significantly different between the two groups. Time in 
light activity have the lowest non-significant P-value (P = 0,070). In total, 7 out of the 22 HD 
patients (31,8%) 5 out of 8 PD patients (62,5%) reached the recommended goal of ≥ 150 






Table 3: ActiGraph registered wear time and physical activity (PA). 
ActiGraph  HD patients (n = 22) PD patients (n = 8) P 
Wear Time Accelerometer (min) 9194,5 (8501-9733) 7509 (6400-9134) 0,024 
Daily Average of Sedentary Bouts (min) 676,2 (565,1-770,4) 680,1 (631,3-788,9) 0,475 
Daily Average of Sedentary Breaks (min) 742,4 (653,2-837,2) 710,3 (641-787,5) 0,344 
Time in light activity (min) 8596,4 (7285-9185,3)  9145,3 (8709,2-9918,3)  0,070 
- Percent in light activity 98,8% (2,2%) 98,4% (1,6%) 0,945 
Time in MVPA total (min) 98,9 (37,6-203,5) 157,7 (51,4-197,2) 0,534 
- Percent in MVPA 1,2% (2,2%) 1,6% (1,6%) 0,945 
        -       Subjects with ≥ 150 min MVPA weekly 7 (31,8%) 5 (62,5%) 0,129 
Average MVPA per Day (min) 13,3 (5,4-29,1) 22,5 (8,1-28,2) 0,504 
Average Steps per Day 1972,5 (1160,3-3673) 2687,3 (1265-3798) 0,730 
Data are shown in median (interquartile range) and number (percent). Abbreviations: MVPA – Moderate to 
vigorous activity 
 
Figure 2 shows that only one patient who 
was treated with dialysis had an active 
lifestyle in terms of average steps daily (≥ 
7500), three patients classified to 
somewhat active (5000-7499 steps/day), 
whereas 26 were categorised as sedentary. 
In total, >7500 steps per days (“active”) 
were recorded for 10 days, 5000-7500 steps 
(“somewhat active”) for 22 days, whereas 
number of steps per day were classified as 
sedentary for 174 of the 206 accelerometer 
recording days.  
5.2.3 Correlation coefficients 
In Table 4 , Spearman correlation coefficients between covariates believed to affect physical 
condition and average steps per day, as well as average daily MVPA, are shown. There were 
no significant correlations. However, there is a borderline non-significant negative 
correlation between haemoglobin and the dichotomous variable of daily average of MVPA 












Average daily steps Total number of days
step counts
Active (≥ 7500 steps/day) 
Somewhat active (5000-7499 steps/day)
Sedentary (< 5000 steps/day)
Figure 2: Frequency of patients with average daily 
steps and total number of days with step counts 





Table 4: Correlations 
Variable r – steps per day above median. P r – daily MVPA above median. P 
Age years - 0,320 0,085 - 0,359 0,052 
BMI kg/m2   0,062 0,746 0,100 0,598 
Diabetes yes - 0,283 0,130 - 0,236 0,209 
No drugs - 0,101 0,597 - 0,167 0,379 
Haemoglobin g/dL - 0,276 0,147 - 0,359 0,056 
Albumin g/L - 0,091 0,639   0,021 0,915 
Creatinine µmol/L - 0,058 0,766 -0,049 0,799 
Univariate correlations (r=Spearman’s rho) of baseline variables with the dichotomous variables average steps 
per day above median and average daily moderate to vigorous activity (MVPA) above median combined for HD 
and PD patients.  
 
In a multivariable logistic regression analysis, haemoglobin was significantly associated with 
the dichotomous variable average daily MVPA at or above vs. below median (OR 0,39 (95% 
CI 0,15-0,99) per 1 g/dL increase; p = 0,047). None of the other variables in the model (age, 
BMI, diabetes, number of drugs, albumin, creatinine) were significantly associated with any 
of the two outcome variables.  
5.2.4 Knowledge about barriers against physical activity 
Figure 3 shows that 16 patients 
reported that they had not 
been informed by their 
nephrologist about the 
importance of PA (13 patients 
did not respond to the 
question). Nineteen patients 
claimed that they wanted to be 
more physically active than 
they were at the time of 
registration, whereas three stated that they did not wish they were more active (two 
patients responded “do not know”; six did not respond). 
Figure 4 shows that complications from comorbidities was the barrier/obstacle 12 patients 
considered to be moderate/high. Time used on dialysis treatment, complications from 




















to you about the
importance of
physical activity?




Yes No Do not know/do not remember Missing
Figure 3: Information about physical activity and number of patients 







In the present study we assessed PA and HRQOL among patients in HD and PD dialysis. We 
measured PA with a questionnaire and an accelerometer worn during a week, and according 
to our knowledge, this has never been done previously in HD and PD patients 
simultaneously. 
6.1 Physical activity in dialysis patients and differences in HD and PD 
The results of this study did not show any significant differences between HD and PD 
patients in the amount of self-reported and objectively measured PA. For HRQOL scores only 
role limitations due to physical health were significantly higher among PD patients compared 
to patients in HD. This may indicate that our group of HD patients have more severe physical 
health obstacles to overcome in terms of filling their role in everyday life. PD patients may 
experience fewer health problems that interfere with them doing what is expected from 
others or themselves. However, this is only one domain in the SF-questionnaire, and we 
found no significant differences between the groups in other domains. Moreover, self-
reported, subjective data should be interpreted with caution. Numerically, both the average 
daily MVPA and the average number of steps performed by PD patients exceeded the 
























































I do not know
how to start up
with physical
activity
What are the most important barriers against physical activity? 
Missing No/low barrier Moderate/high barrier





significance. The lack of between-group differences may be due to the low sample size and 
selection bias. The objective measurements, using an accelerometer, gives an indication that 
dialysis patients mostly perform light PA, and are more restrictive in moderate to vigorous 
PA This is an interesting finding, because 30 minutes MVPA a day 5 times a week or 150 
minutes MVPA a week is the recommended amount of PA also in dialysis patients. Vigorous 
training may be too comprehensive to conduct for many patients in these groups, but a 
focus on moderate activity may be needed. 
6.2 Selection of patients and other study limitations 
Although the number of asked patients were 107, only 30 subjects participated in the study, 
22 HD and 8 PD patients. This is a relatively small number of subjects, below the number we 
expected. There may be many reasons for that. First, the study was carried out in multiple 
centres, varying in size and staff. HD satellites are typically run by skilled dialysis nurses only, 
whereas in hospitals both nephrologists, nephrology trainees and dialysis nurses are directly 
involved in patient treatment. All the centres were informed orally and by written material 
about the aims and scope of the project. However, the actual project period was short, and 
limited spare time in a busy clinical setting, as well as the lack of at least one dedicated 
project collaborator at each site, probably affected patient information and recruitment. 
Also, PD patients in the region have a long distance to the dialysis centre, and therefore 
infrequent visits. Therefore, some eligible patients were not informed and invited to 
participate, or they were recruited too late. Furthermore, as one of the exclusion criteria 
was open to individual clinical judgement (“Patients considered by a nephrologist as not 
suitable due to a high load of physical and/or mental comorbidity”), it could not be ruled out 
that the various health workers (doctors and nurses, respectively) would influence the 
recruitment by evaluating this criterion differently.  
Second, in the recruiting process there may have been a spread of negative mentality 
between patients in the same dialysis unit, and this may be a partial reason why a lower 
number of patients than expected joined our study. Third, some patients expressed that 
their main reason for rejecting study participation, was that revealing their low PA level 





studies. Based on the baseline characteristics presented in Table 1, which is similar to the 
mean values provided in the Norwegian Renal Registry, we believe that our cohort was fairly 
representative for eligible patients (12). The characteristics of included HD and PD patients, 
respectively, were similar, except a significantly longer median distance to the nearest 
dialysis centre for PD patients. This was expected since some of patients are treated with PD 
are offered this treatment modality mainly due to a long distance to the dialysis centre. 
6.3 Comparison of physical activity to other studies on dialysis patients 
According to our knowledge, few other studies on dialysis patients have assessed PA using 
an accelerometer, and most are only conducted on HD patients. However, a study from 
Japan with 202 eligible HD patients wearing an uniaxial accelerometer for seven days 
showed a median (interquartile range) daily steps of 3925 (2287-6244)(39). This is a 
considerably higher number of steps compared to the findings in our study. In the Japanese 
study, median age of the included patients was 64 (57-72) and 52% were women. Our HD 
study population consisted mostly of men, and this may be a factor potentially explaining 
the difference in step counts. In terms of comorbidity, 38,6% of the subjects had diabetes 
mellitus, which is similar to our percentage.  
A study conducted on 19 HD patients aged ≥ 18 and < 65 years with a triaxial accelerometer 
worn 12 hours daily for four days showed a mean ±SD of daily steps 5648 ± 2870 (40). This 
Brazilian study also showed a higher number of steps taken compared to our study. 
However, an important difference compared to our study was a lower mean age of the 
subjects (47,5 ± 12,5 years). Furthermore, the percentage of diabetes was considerably 
lower in the Brazilian study (10,5% of the subjects) compared to our study.  
In another study from Brazil, ActiGraph GT3X was used to register PA in 79 HD patients for 
one full week. Whereas 22 patients (35,5%) in this study achieved ≥ 150 minutes MVPA per 
week (41). In our study, seven out of the 22 HD patients (31,8%) managed to get ≥ 150 
minutes MVPA in total during the study. The methods are quite similar between the studies 
and this may indicate that MVPA registered in our study is representative for HD patients. 





observational studies so far suffer from low numbers of participants, both differences and 
similarities should be interpreted with care. Moreover, differences in daily step count may 
be affected not only by exercise patterns, but also by logistic differences such as differences 
in availability of transportation etc.  
6.4 Comparison of physical activity with other patient groups 
This study focused on differences between HD and PD patients, and we did not have any 
control group. However, our results may be compared to historical data published in the 
literature. By comparing our data to measurements made in a general population, the 
impact from a serious chronic disease on PA may be illustrated. On the other hand, it is also 
of interest to compare the results from dialysis patients with similar measurements done in 
patients with other chronic conditions, such as heart failure.  
An American study conducted in 2018 with accelerometer measurements of PA among 182 
patients with heart failure, used the same device, ActiGraph GT3X, as we did for 7 full days 
of measurement, with a minimal wear time of 4 days in total and 10 hours daily to be 
included in the results (42) However, they applied the Freedson 1998 et al cut points, that 
uses the vertical axis of movement alone to calculate time in different activity categories, 
whereas we used Freedson Adult VM3 cut points with three axes in our study. Regardless of 
the methodological differences, it is interesting to compare groups in terms of average 
minutes daily of MVPA and steps. Participants in our study had median (interquartile range) 
average MVPA per day (min) 13.3 (5,4-29,1) patients in HD and 22.5 (8,1-28,2) patients in 
PD. However, mean SD average daily minutes of MVPA in patients with heart failure 
classified as New York Heart Association (NYHA) class I was 13.0 (9.4), 12.4 (11.9) in NYHA 
class II and only 6.4 (6.8) in NYHA class III and IV (42). Although our measurements are listed 
as medians, and the results in the heart failure study are given as means, we get the 
impression that time is spent on MVPA in HD and PD patients in Northern Norway is 
comparable to MVPA in this group of American heart failure patients with the least symptom 
load (NYHA class I). This was somewhat unexpected as patients on chronic dialysis are 
recognised as a group with a high burden of symptoms. However, there may be several 





role, but the fact that our study included a smaller number of subjects than the heart failure 
study, and a selection bias towards healthier patients may be the most important factors. 
However, for indication purposes we think it is a suitable comparison. 
6.5 Comparison of physical activity with healthy people 
A study conducted in Norway, with focus on self-reported PA and objectively measured PA, 
i.e. data from The Tromsø Study, gives us a valid basis for comparison of our patient group to 
the general population with regards to average daily MVPA and steps. The objective PA data 
was collected with ActiGraph GT1M during 7 consecutive days with 15-second epochs and a 
minimum of 10-hour activity daily for at least 3 days to be included in the analysis. Women 
(n = 136) achieved mean daily average MVPA of 37,6 minutes, and men 36,8 minutes (43). 
Compared with our results, we saw a considerably higher amount of MVPA in the healthy 
cohort. This difference was expected. In terms of steps daily, women in the healthy cohort 
had a mean of 8727 steps daily and men 8109 (43). Comparison with the median steps in our 
study shows that there is a big difference between daily step count among dialysis patients 
and persons from the general population. This may indicate that dialysis patients have a 
potential to move more during the day.  
6.6 Possible predictors of physical activity 
In our aim to map out biological factors that may be associated with the amount of PA, we 
only found a borderline non-significant small negative correlation of -0,359 (P = 0,056) 
between haemoglobin and average MVPA. However, our study was small and not powered 
to assess predictors of PA, and therefore the results of this study should be interpreted with 
caution. However, whether biological factors are associated with PA is an important 
question that needs to be assessed in larger studies with less missing data. 
6.7 Attitudes and barriers 
Factors and barriers that limit PA were an interesting area of our survey. Our patients gave a 
clear indication that nephrologists working with them did not focus on the importance of PA. 
Only one patient reported that he/she had been informed about this from his/her 





this question, we believe that this is an area where nephrologists and other health 
professionals can – and should - improve. The fact that as many as 19 patients expressed a 
wish to become more active underlines the need for improvement in this area. Diseases 
other than kidney disease was the factor most frequently ranked by the participants as a 
moderate/high barrier to PA. This may indicate that many patients on chronic dialysis 
struggle with co-morbidities that are limiting in terms of exercising. Dialysis patient 
populations are complex and may need a broad approach to help them become more 
physically active. The results of our study can be used in a constructive way as a reminder to 
us that we are dealing with patients who want, but do not necessarily manage or know how 
to become more physical active. A combination of better information and motivation from 
health workers in contact with dialysis patients may contribute to a higher percentage of the 
patients understanding the benefits of PA and getting the right tools to start. Another 
suggestion is to offer activities specifically suited for patients on dialysis. We do clearly see 
from our study that patients want to be more active, so starting up training groups for 
dialysis patients may be an interesting interventional study in the future. In this regard, the 
long time spent on treatment as well as considerable travel distances to the dialysis unit may 
be challenging; these factors were also mentioned by a number of patients as a barrier to 
PA.  
6.8 The use of accelerometer measurements in dialysis patients 
We do believe that ActiGraph registration a suitable method for studying PA in dialysis 
patients. We did not receive negative feedback from the subjects wearing them, and the 
devices were considered user friendly with instructions that were easy to understand. 
Patients were instructed to wear the device for one week, and therefore median wear time 
in minutes HD 9194,5 (8501-9733) and PD 7509 (6400-9134), was satisfactory. Only one 
subject had a wear time <4 days, which is often seen as an exclusion criterion in other 
studies. The fact that registrations are poor for upper limb movements makes the ActiGraph 
devices less useful in patients with walking disabilities, such as patients who have had limb 
amputations. However, despite this limitation, we believe that ActiGraph is well suited to 






Our main objective was to study the degree of PA of patients on HD and PD in Northern 
Norway, and, as far as we are aware of, an accelerometer was used for the first time to 
measure activity in both HD and PD patients. Study results indicate that dialysis patients 
have a low level of PA based on average daily MVPA and step count, compared to healthy 
persons. We found no significant differences between patients on the two different dialysis 
modalities, but small group sizes limit firm conclusions. A high haemoglobin level was 
associated with less daily MVPA. Most patients reported that they had never been informed 
by their nephrologist about the potential benefit of being physically active, but a desire to be 
more active was commonly found. Barriers to PA included comorbidities and time spent on 
treatment. We believe there is potential to raise awareness of PA in health workers being 
involved in dialysis treatment, and to increase PA levels in dialysis patents. We hope this 
study can be used as a catalysator for future observational and interventional studies on PA 
in patients on dialysis. 
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Appendix 1: Questionnaire 
Spørreskjema til deltakerne i studien «Kartlegging av fysisk aktivitet hos dialysepasienter i 
Nord-Norge – en observasjonsstudie» 
Dette spørreskjemaet handler om hvordan du ser på din egen helse, hvordan du vurderer 
din egen fysiske aktivitet og hvilke forhold som eventuelt hindrer deg fra å være mer aktiv. 
Sammen med aktivitetsmålingen vi gjør i denne studien, bidrar dine svar til å og oss mer 
kunnskap om sammenhengen mellom dialysebehandling og fysisk aktivitet hos personer 
som har langt kommet kronisk nyresykdom.  
Du  trenger ikke å svare på alle spørsmålene på én gang, men det er fint om du er ferdig med 
å fylle ut skjemaet før du skal levere ActiGraph tilbake.   
Hvis du er i tvil om ordlyden i spørreskjemaet eller har andre spørsmål eller kommentarer, 
kan du kontakte dialyselegen eller –sykepleieren du vanligvis forholder deg til, så formidler 
de kontakt til prosjektmedarbeiderne. 

















1. Stort sett, vil du si at din helse er:  
1 Utmerket   2 Meget god   3 God   4 Nokså god  5 Dårlig  
 
2. Sammenliknet med for ett år siden, hvordan vil du si at din helse stort sett er nå?  
1 Mye bedre nå enn for ett år siden    2 Litt bedre nå enn for ett år siden   
3 Omtrent den samme som for ett år siden   4 Litt dårligere enn for ett år siden  
5 Mye dårligere enn for ett år siden  
3. De neste spørsmålene handler om aktiviteter du kanskje utfører i løpet av en vanlig dag.  
Er din helse slik at den begrenser deg i utførelsen av disse aktivitetene nå? Hvis ja, hvor mye? 
AKTIVITETER         Ja, begrenser              Ja, begrenser  Nei, begrenser meg 
           meg mye   meg litt       ikke i det hele tatt 
 
a. Anstrengende aktiviteter som å løpe, 
løfte tunge gjenstander, delta i  
anstrengende idrett           
 
b. Moderate aktiviteter som å flytte  
et bord, støvsuge, gå en tur eller              
drive med hagearbeid           
 
c.  Løfte eller bære en handlekurv          
 
d.  Gå opp trappen flere etasjer          
 
e.  Gå opp trappen en etasje          
f.  Bøye deg eller sitte på huk          
g.  Gå mer enn to kilometer          
h.  Gå noen hundre meter           
i.  Gå hundre meter           





4. I løpet av de siste 4 ukene, har du hatt noen av følgende symptomer i ditt arbeid eller i andre av dine 
daglige gjøremål på grunn av din fysiske helse? 
Ja   Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller andre gjøremål     
b. Du har utrettet mindre enn du har hadde ønsket        
c. Du har vært hindret i å utføre visse typer arbeid eller gjøremål      
d. Du har hatt problemer med å gjennomføre arbeid eller andre gjøremål  
(f.eks. fordi det krevde ekstraanstrengelser)         
 
5. I løpet av de siste 4 ukene, har du hatt noen av følgende symptomer i ditt arbeid eller i andre av dine 
daglige gjøremål på grunn av følelsesmessige problemer (som f.eks. å være deprimert eller engstelig)? 
Ja   Nei 
a. Du har måttet redusere tiden du har brukt på arbeid eller andre gjøremål     
b. Du har utrettet mindre enn du har hadde ønsket        
c. Du har hatt utført arbeid eller andre gjøremål mindre grundig 





6. I løpet av de siste 4 ukene, i hvilken grad har din fysiske helse eller følelsesmessige problemer hatt 
innvirkning på din vanlige sosiale omgang med familie, venner, naboer eller foreninger? 
Ikke i det hele tatt  Litt   En del   Mye  
 
 
7. Hvor sterke kroppslige smerter har du hatt i løpet av de siste 4 ukene? 







8. De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det de siste fire 
ukene. For hvert spørsmål vennligst velg det svaralternativ som best beskriver hvordan du har hatt det. 
Hvor ofte i løpet av de siste fire ukene har du: 
    Hele Nesten hele Mye av  En del av Litt av  Ikke i det 
    tiden tiden  tiden  tiden  tiden  hele tatt 
 
a. Følt deg full av tiltakslyst           
b. Følt deg veldig nervøs           
c. Vært så langt nede at  
ingenting kunne muntre 
deg opp             
 
 
d. Følt deg rolig og  
harmonisk             
 
e. Hatt mye overskudd           
f. Følt deg nedfor og trist           
g. Følt deg sliten            
h. Følt deg glad            
i. Følt deg trett            
9. Hvor RIKTIG eller GALT er hver av de følgende påstandene for deg? 
        Helt  Delvis  Vet  Delvis Helt  
        riktig riktig ikke galt galt 
  
 
a. Min nyresykdom forstyrrer for mye i livet mitt       
b. Jeg bruker for mye av tiden min på nyresykdommen min      
c. Det er frustrerende å beskjeftige seg med nyresykdommen  
min             
 






10. I løpet av de siste 4 uker, hvor mye har du vært plaget av følgende (Sett kryss i én boks på hver linje) 
       Ikke plaget Litt Noe Mye  Veldig 
mye  
       i det hele tatt plaget plaget plaget  plaget 
 
a. Ømme muskler            
 
b. Brystsmerter            
 
c. Kramper             
 
d. Hudkløe             
 
e. Tørrhud             
 
f. Kortpustethet            
 
g. Svimmelhet eller nesten besvimelse         
 
h. Mangel på appetitt           
 
i. Utkjørt eller utbrent           
 
j. Nummenhet i hender og føtter          
 
k. Kvalme eller brekninger           
 
 
(Besvares kun av pasienter i hemodialyse): 
l. Problemer med dialysetilgangen  
(fistel, graft, kateter)           
 
 
(Besvares kun av pasienter i peritoneal dialyse): 








11. Noen personer er plaget av nyresykdommen i det daglige liv, mens andre ikke er det. Hvor mye 
plaget er du av din nyresykdom innen hvert av de følgende områder? (Sett i én boks på hver linje) 
 
Ikke plaget Litt Noe Mye Veldig mye  
       i det hele tatt plaget plaget plaget plaget 
 
 
a. Begrensninger i hvor mye du kan drikke         
 
b. Kostrestriksjon            
 
c. Din evne til å klare arbeid i huset          
 
d. Din evne til å reise           
 
e. Din avhengighet av leger 
og annet helsepersonell           
 
f. Stress og bekymring forårsaket 
av din nyresykdom            
 
 
12. Hvor ofte de siste 4 uker har du... (Sett kryss i én boks på hver linje) 
    Ikke i det Litt av  En del   Mye av  Nesten hele Hele 
    hele tatt tiden  av tiden tiden  tiden  tiden 
 
a. Våknet om natten og 
hatt problemer med å  
sovne igjen              
 
b. Fått den mengden søvn  
som du trenger            
  
c. Hatt problemer med å   







13. a. Hvor mange dager i løpet av den siste uka har du drevet med meget anstrengende fysiske 
aktiviteter som tunge løft, gravearbeid, aerobics eller sykle fort? Tenk bare på aktiviteter som varer 
minst 10 minutter i strekk  
  dager per uke 
 ingen (gå til spørsmål 14.a) 
 
 
. 13.b. På en vanlig dag hvor du utførte meget anstrengende fysiske aktiviteter, hvor lang tid brukte du 
da på dette?  
.   timer   minutter   Vet ikke/husker ikke 
14. a. Hvor mange dager i løpet av den siste uka har du drevet med middels anstrengende fysiske 
aktiviteter som å bære lette ting, sykle eller jogge i moderat tempo eller mosjonstennis? Ikke ta med 
gange, det kommer i neste spørsmål. 
 dager per uke 
 ingen (gå til spørsmål 15.a) 
 
14.b. På en vanlig dag hvor du utførte middels anstrengende fysiske aktiviteter, hvor lang tid brukte du 
da på dette? 
.   timer   minutter   Vet ikke/husker ikke 
. 15. a. Hvor mange dager i løpet av den siste uka gikk du minst 10 minutter i strekk for å komme deg fra 
ett sted til et annet? Dette inkluderer gange på jobb og hjemme, gange til buss, eller gange som du gjør 
på tur eller som trening i fritiden  
 dager per uke 
 ingen (gå til spørsmål 16) 
 
15.b. På en vanlig dag hvor du gikk for å komme deg fra et sted til et annet, hvor lang tid brukte du da 
totalt på å gå?  
.   timer   minutter   Vet ikke/husker ikke 
16. Dette spørsmålet omfatter all tid du tilbringer i ro (sittende) på jobb, hjemme, på kurs, og på 
fritiden. Det kan være tiden du sitter ved et arbeidsbord, hos venner, mens du leser eller ligger for å se 
på TV. 
I løpet av den siste uka, hvor land tid brukte du vanligvis totalt på å sitte på en vanlig hverdag? 





17. Har nyrelegen noen gang snakket med deg om viktigheten av å være fysisk aktiv? 
Ja    Nei    Vet ikke/husker ikke   
18. Har du et ønske om å være mer fysisk aktiv enn du er i dag? 
Ja    Nei    Vet ikke  
19. Hvis du svarte “ja” på forrige spørsmål, hvilke forhold tenker du er dine viktigste hindre for fysisk 
aktivitet? 
      Ikke et hinder Litt hinder Middels stort hinder Stort hinder 
a. Tiden jeg bruker 
på dialysebehandlingen           
 
b. Tiden jeg bruker på å reise 
til og fra dialysebehandlingen         
c. Plager jeg får av  
dialysebehandlingen           
d. Plager jeg får av 
medisiner jeg tar            
e. Plager jeg får av  
nyresykdommen           
f. Plager jeg får av  
andre sykdommer jeg har          
g. Jeg har aldri tidligere vært  
interessert i fysisk aktivitet          
h. Jeg vet ikke hvordan jeg 














20. Til deg som behandles med hemodialyse: Kunne du tenke deg: 
        Ja   Nei          Vet ikke 
a. Å trene mens du får dialysebehandling?         
b. Å trene før dialysebehandlingen?          
 
21. Til deg som behandles med peritoneal dialyse: Kunne du tenke deg: 
        Ja   Nei           Vet ikke 
a. Å trene i gruppe på sykehuset der  
du går til kontroll, sammen med andre 
som behandles med PD?           
 
b. Å trene i gruppe på mitt hjemsted?         
 




23. Hvor mange kilometer er det fra ditt hjem til ditt dialysesenter (evt. det sykehuset der du går til PD-
kontroll)? 






24. Når du skal til dialyse eller dialysekontroll, hvilket klokkeslett reiser du vanligvis hjemmefra? 
Klokken:    
 
25. Hvilket klokkeslett er du vanligvis hjemme igjen?  
Klokken:    
 










Appendix 2: Information to patients and written consent 
FORESPØRSEL OM DELTAKELSE I FORSKNINGSPROSJEKT 
«En undersøkelse av fysisk aktivitet blant dialysepasienter i Nord-Norge» 
BAKGRUNN OG FORMÅL MED PROSJEKTET 
Hos mange personer som behandles regelmessig med dialyse, bidrar både nyresykdommen 
og behandlingen til at de er mindre fysisk aktive enn andre. Forskning tyder likevel på at 
fysisk aktivitet kan være gunstig for fysisk helse og livskvalitet også hos personer i dialyse.  
Det finnes ingen tidligere forskningsstudier av fysisk aktivitet blant personer som er i 
behandling med dialyse i Nord-Norge. Vi vil med dette spørre deg om du vil være med på 
den aller første.  
Hensikten med studien er å undersøke om økt fysisk aktivitet har sammenheng med økt 
livskvalitet. For å undersøke dette vil vi gjennomføre en spørreundersøkelse med spørsmål 
rundt dine aktivitetsvaner. Vi vil også be deg om å gå med en aktivitetsmåler i sju dager for å 
måle mengden fysisk aktivitet i denne perioden. 
Forskningsstudien kom i stand som et studentprosjekt ved medisinutdanningen, UiT Norges 
Arktiske Universitet. Den er utformet av leger og studenter ved Universitetssykehuset i 
Nord-Norge/UiT og Nordlandssykehuset Bodø. Vi har også viktige samarbeidspartnere blant 
nyrelegene ved Finnmarkssykehuset og Helgelandssykehuset. Videre støttes prosjektet 
økonomisk av Landsforeningen for Nyresyke og Transplanterte (LNT). 
HVA INNEBÆRER DET Å DELTA? 
Dersom du samtykker til å delta, vil du få utdelt et spørreskjema med spørsmål rundt dine 
aktivitetsvaner og din livskvalitet. Det er ønskelig at du svarer så godt du klarer på flest mulig 
av spørsmålene.  
Videre vil du gå med en liten aktivitetsmåler rundt høyre hofte i sju dager. Dette er en liten 
databrikke som festes ved høyre hofte og som kun vil registrere hvor mye du beveger deg. 
Brikken registrerer ikke hva du holder på med eller hvor du er. Sammen med brikken leverer 
vi ut en god beskrivelse av hvordan den skal festes og brukes. Vi vil avtale nærmere med deg 
hvor og hvordan du aktivitetsmåleren blir utdelt og tilsvarende hvor og hvordan du skal 
levere den inn igjen. Bruk av ActiGraph vil forekomme i tidsrommet mellom 15. november - 
15.desember. 
For å få et best mulig bilde av det fysiske aktivitetsnivået hos personer i dialyse, og hva som 
eventuelt begrenser aktiviteten, ønsker vi å registrere noen opplysninger om din sykdom 





blodprøvesvar) og dialysebehandling (type dialysebehandling, hvor lenge du har vært i 
behandling, reiseavstand og –tid til dialysen eller nyrelegen). Opplysningene ønsker vi å 
hente fra din medisinske journal. Vi vil be om ditt samtykke til innsyn i journalen for å finne 
disse spesifiserte opplysningene.  
MULIGE FORDELER OG ULEMPER 
Deltagelse vil innebære noe tidsbruk for deg i utfyllingen av spørreskjemaet. Det vil også ta 
litt tid å betjene aktivitetsmåleren (av/på under dusj/bad o.l). Aktivitetsmålerne som brukes i 
studien, vil ikke medføre ubehag eller smerter, og vil kunne sammenlignes med et belte når 
den er i bruk.  
Kunnskapen vi får fra denne studien vil kunne bidra til å forbedre framtidige anbefalinger om 
fysisk aktivitet blant personer som behandles med dialyse. 
HVA SKJER MED INFORMAJSONEN OM DEG? 
All informasjon som innhentes om deg i denne forskningsstudien, vil kun bli brukt for å 
besvare de spørsmålene vi har skissert over (se «Bakgrunn og formål med prosjektet» over). 
Data som innhentes, vil samles og lagres på en sikker måte, i samsvar med nasjonale 
forskrifter og slik det kreves av Personvernombudet ved hvert av de fire involverte 
helseforetakene. Det er kun autorisert personell knyttet til prosjektet som har adgang til 
navnelisten der ditt ID-nummer er konstruert, og som kan finne tilbake til deg.  
Det vil ikke være mulig å identifisere deg i resultatene av studien når denne publiseres. 
Studien har vært vurdert av Regionale komiteer for medisinsk og helsefaglig forskning 
avdeling Nord (REK Nord), som ikke har stilt spesielle krav til forskningen.   
FRIVILLIG DELTAKELSE 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke om deltakelse. Dersom du ønsker å delta i studien, ber vi om at du undertegner 
samtykkeerklæringen på siste side. Dersom du har spørsmål til studien kan du kontakte: 
Kjell-Gunnar Vangen, Medisinstudent Universitetet i Tromsø, Tlf: xxxxxxxx 
Marit Dahl Solbu, overlege og spesialist i nyresykdommer, Universitetssykehuset Nord-
Norge, Tlf: xxxxxxxx 
Du kan også stille dine spørsmål til din nyrelege eller dialysesykepleier, som kan formidle 






SAMTYKKE TIL DELTAKELSE I FORSKNINGSSTUDIE:  
«En undersøkelse av fysisk aktivitet blant dialysepasienter i Nord-Norge» 
Jeg har fått muntlig og skriftlig informasjon om forskningsstudien. 
 
……………………………………………………………………………………………………………………………… 
Lege/sykepleier bekrefter å ha informert om studien (sted/dato/navn/underskrift) 
 
Jeg samtykker herved til å delta i studien. Mitt samtykke omfatter også innhenting av 







Sted/dato    Signatur, prosjektdeltaker 
 
 
Navnelapp 
 
 
40 
 
GRADE 
 
 
41 
 
 
 
42 
 
 
 
43 
 
 
 
44 
 
 
 
45 
 
 
